Sierra Oncology, Inc (SRRA)

Etorro trading 970x250
Sierra Oncology, Inc (SRRA) Logo

About Sierra Oncology, Inc

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California. Address: 1820 Gateway Drive, San Mateo, CA, United States, 94404

Sierra Oncology, Inc News and around…

Latest news about Sierra Oncology, Inc (SRRA) common stock and company :

Monday 11/29 Insider Buying Report: SRRA, MNRO
29 Nov, 2021 FinancialContent

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two noteworthy recent insider buys.

Pick Up This Bargain Even Cheaper Than Director Collard Did
29 Nov, 2021 FinancialContent

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy. Back on November 24, Sierra Oncology Inc's Director, Craig A..

Insider Buying: Craig Collard Just Spent US$311k On Sierra Oncology, Inc. (NASDAQ:SRRA) Shares
26 Nov, 2021 Yahoo! Finance

Potential Sierra Oncology, Inc. ( NASDAQ:SRRA ) shareholders may wish to note that insider Craig Collard recently...

Sierra Oncology Announces Presentation at Jefferies London Healthcare Conference
12 Nov, 2021 FinancialContent

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in the 2021 Jefferies London Healthcare Conference. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra, will provide an overview of the company in a presentation that will be available on demand beginning at 8:00 am GMT (3:00 am ET) on Thursday, November 18, 2021, to conference attendees.

ORIC Pharmaceuticals Appoints Angie You, Ph.D., to its Board of Directors
10 Nov, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. “We are delighted to welcome Angie to ORIC’s board of directors,” said Jacob Chacko, M.D., preside

Sierra Oncology Reports Third Quarter 2021 Results
05 Nov, 2021 FinancialContent

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the third quarter ended September 30, 2021.“The past several months have been quite productive for Sierra with the addition of SRA515 to our pipeline and preparing for momelotinib pivotal data,” said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology. “We remain focused on the completion of the MOMENTUM study and look forward to sharing topline results by February next year.”

Sierra Oncology Announces Momelotinib Poster Accepted for Presentation at ASH
04 Nov, 2021 FinancialContent

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced new retrospective analyses of the momelotinib Phase 3 SIMPLIFY studies will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting being held virtually and in Atlanta, GA December 11-14, 2021.

Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 Nov, 2021 FinancialContent

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to three new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into employment with Sierra, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

A Sierra Oncology, Inc. (NASDAQ:SRRA) insider increased their holdings last year
19 Oct, 2021 Yahoo! Finance

Insiders were net buyers of Sierra Oncology, Inc.'s ( NASDAQ:SRRA ) stock during the past year. That is, insiders...

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
27 Sep, 2021 FinancialContent

Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:SEEL) was changed from Neutral ...

Sierra Oncology to Present at Three September Investor Conferences
07 Sep, 2021 FinancialContent

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology will provide a company update at the HC Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit. He will participate in a fireside chat discussion at the 2021 Cantor Virtual Global Healthcare Conference.

Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding
09 Aug, 2021 FinancialContent

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The company now expects topline data from the Phase 3 registration-enabling MOMENTUM study by February 2022, and assuming positive results, the company plans to file a New Drug Application with the U.S. Food & Drug Administration in Q2 2022.

Sierra Oncology Bets $216M On AstraZeneca's BET Inhibitor For Myelofibrosis
06 Aug, 2021 FinancialContent

Sierra Oncology Inc(NASDAQ: SRRA) hasacquired an exclusive global licensefromAstraZeneca Plc(NASDAQ: ...

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

 Sierra Oncology Reports Second Quarter 2021 Results
05 Aug, 2021 FinancialContent

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the second quarter ended June 30, 2021.

Sierra Oncology Reports Second Quarter 2021 Results
05 Aug, 2021 Yahoo! Finance

SAN MATEO, Calif., August 05, 2021--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the second quarter ended June 30, 2021.

 Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
05 Aug, 2021 FinancialContent

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (LSE/STO/NASDAQ: AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022.

Sierra Oncology Signs Exclusive Global In-Licensing Agreement with AstraZeneca for Novel BET Inhibitor to Expand Myelofibrosis Pipeline
05 Aug, 2021 Yahoo! Finance

SAN MATEO, Calif., August 05, 2021--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (LSE/STO/NASDAQ: AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in t

SRRA Crosses Below Key Moving Average Level
03 Aug, 2021 FinancialContent

In trading on Tuesday, shares of Sierra Oncology Inc (SRRA) crossed below their 200 day moving average of $16.59, changing hands as low as $15.32 per share. Sierra Oncology Inc shares are currently trading off about 9.1% on the day..

Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
22 Jul, 2021 FinancialContent

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted a stock option to a new employee as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
13 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Is Sierra Oncology (NASDAQ:SRRA) In A Good Position To Deliver On Growth Plans?
13 Jul, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Sierra Oncology...

58 Biggest Movers From Yesterday
13 Jul, 2021 FinancialContent

Gainers MediaCo Holding Inc. (NASDAQ: MDIA) shares jumped 311.6% to close at $17.00 on Monday after jumping 20% on Friday. State ...

8 Chart set-ups to watch next week
26 Jun, 2021 FinancialContent
Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial
21 Jun, 2021 Yahoo! Finance

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic. The study enrolled 195 patients based on a planned 180 patients across 21 countries. Topline data are anticipated in Q1 2022, a

Sierra Oncology Hosting KOL Panel Event to Discuss Momelotinib Data Presented at EHA 2021
14 Jun, 2021 Yahoo! Finance

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced it will host an analyst and investor event on Monday, June 21 at 4:30 pm ET. The event will feature three leading myelofibrosis experts:

Momelotinib Oral Presentation at European Hematology Association Demonstrates Association Between Transfusion Independence and Improved Overall Survival
11 Jun, 2021 Yahoo! Finance

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced data presented at the European Hematology Association (EHA) Annual Meeting highlighting transfusion independence with momelotinib is associated with improved overall survival, including in patients with anemia at baseline. In addition, transfusion independence is seen irrespective of baseline degree of anemia, platelet count or transfusion

Sierra Oncology Welcomes Two New Independent Directors to its Board
03 Jun, 2021 Yahoo! Finance

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced Georgia Erbez and Christy Oliger have joined the Company's Board of Directors. Ms. Erbez is Chief Financial Officer at Harpoon Therapeutics. Ms. Oliger currently serves on the Board of Directors at Karyopharm Therapeutics and Reata Pharmaceuticals, and most recently was Senior Vice President of the Oncology Business Unit at Genentech. Toge

Sierra Oncology Announces Presentation at Jefferies Healthcare Conference
25 May, 2021 Yahoo! Finance

Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that the company will participate in the 2021 Jefferies Healthcare Conference being held virtually from June 1-4, 2021. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra will present an overview of the company on Thursday, June 3 from 1:30 – 1:55 pm ET.

Sierra Oncology Announces Abstracts Accepted for American Society of Clinical Oncology Annual Meeting
19 May, 2021 Yahoo! Finance

—New momelotinib analysis examining the association between transfusion independence and overall survival to be presented—

Sierra Oncology, Inc (SRRA) is a NASDAQ Common Stock listed in , ,

970x250